Poongjeon PharmacyLTD（A298060）株式概要SCMライフサイエンス株式会社は、幹細胞治療、CMO、受託研究・コンサルティング、化粧品事業を展開している。 詳細A298060 ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性4/6配当金0/6報酬過去5年間の収益は年間4%増加しました。 リスク分析過去1年間で株主の希薄化は大幅に進んだ 最新の財務報告は6か月以上前のものである 意味のある収益がありません ( ₩2B )意味のある時価総額がありません ( ₩31B )すべてのリスクチェックを見るA298060 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value₩Current Price₩3.07k36.2% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-57b6b2016201920222025202620282031Revenue ₩5.8bEarnings ₩1.1bAdvancedSet Fair ValueView all narrativesPoongjeon Pharmacy CO.,LTD. 競合他社MOA Life PlusSymbol: KOSDAQ:A142760Market cap: ₩29.8bNGeneBioSymbol: KOSDAQ:A354200Market cap: ₩31.3bXcell TherapeuticsSymbol: KOSDAQ:A373110Market cap: ₩28.9bKoBioLabsSymbol: KOSDAQ:A348150Market cap: ₩84.0b価格と性能株価の高値、安値、推移の概要Poongjeon PharmacyLTD過去の株価現在の株価₩3,065.0052週高値₩8,375.0052週安値₩3,130.00ベータ0.821ヶ月の変化-33.87%3ヶ月変化-37.77%1年変化-26.67%3年間の変化-94.35%5年間の変化-97.69%IPOからの変化-97.96%最新ニュースBoard Change • May 19No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 1 highly experienced director. No independent directors (3 non-independent directors). CEO & Chairman Byeong-gwan Son was the last director to join the board, commencing their role in 2014. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.お知らせ • Mar 10SCM Lifescience Co., Ltd., Annual General Meeting, Mar 24, 2026SCM Lifescience Co., Ltd., Annual General Meeting, Mar 24, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 7-7, gaetbeol-ro 145beon-gil, yeonsu-gu, incheon South KoreaNew Risk • Feb 15New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (116% increase in shares outstanding). Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Revenue is less than US$5m (₩1.5b revenue, or US$1.1m). Market cap is less than US$100m (₩37.3b market cap, or US$25.9m).お知らせ • Sep 16SCM Lifescience Co., Ltd. announced that it has received KRW 4 billion in fundingOn September 15, 2025, SCM Lifescience Co., Ltd. closed the transaction.お知らせ • Sep 08SCM Lifescience Co., Ltd. announced that it expects to receive KRW 6.999999488 billion in fundingSCM Lifescience Co., Ltd announced a private placement to issue series 2 bearer unsecured convertible bonds for gross proceeds of KRW 2,000,000,000 on September 8, 2025. The transaction will include participation from new investor, Koni New Technology Fund No. 63. The bonds will carry an interest rate of 2% and will have a maturity interest rate of 2%. The bonds will mature on October 2, 2028. The bonds will be 100% convertible into 1,692,047 common shares of the company at a conversion price of KRW 1,182. The conversion period for the bonds will be between October 2, 2026 to September 2, 2028. The transaction has been approved by the board of directors of the company and is expected to close on October 2, 2025. The securities issued in the transaction will be held for a lockup period of 1 year. On the same date, the company will also issue 4,734,848 common shares at an issue price of KRW 1,056 for gross proceeds of KRW 4,999,999,488. The transaction includes participation from new investor, Aria New Technology Fund No. 95. The transaction has been approved by the board of directors of the company and is expected to close on October 2, 2025. The securities issued in the transaction will be held for a lockup period of 1 year.New Risk • Aug 31New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩17b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩17b free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Shareholders have been substantially diluted in the past year (93% increase in shares outstanding). Minor Risks Revenue is less than US$5m (₩1.5b revenue, or US$1.1m). Market cap is less than US$100m (₩39.5b market cap, or US$28.5m).最新情報をもっと見るRecent updatesBoard Change • May 19No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 1 highly experienced director. No independent directors (3 non-independent directors). CEO & Chairman Byeong-gwan Son was the last director to join the board, commencing their role in 2014. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.お知らせ • Mar 10SCM Lifescience Co., Ltd., Annual General Meeting, Mar 24, 2026SCM Lifescience Co., Ltd., Annual General Meeting, Mar 24, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 7-7, gaetbeol-ro 145beon-gil, yeonsu-gu, incheon South KoreaNew Risk • Feb 15New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (116% increase in shares outstanding). Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Revenue is less than US$5m (₩1.5b revenue, or US$1.1m). Market cap is less than US$100m (₩37.3b market cap, or US$25.9m).お知らせ • Sep 16SCM Lifescience Co., Ltd. announced that it has received KRW 4 billion in fundingOn September 15, 2025, SCM Lifescience Co., Ltd. closed the transaction.お知らせ • Sep 08SCM Lifescience Co., Ltd. announced that it expects to receive KRW 6.999999488 billion in fundingSCM Lifescience Co., Ltd announced a private placement to issue series 2 bearer unsecured convertible bonds for gross proceeds of KRW 2,000,000,000 on September 8, 2025. The transaction will include participation from new investor, Koni New Technology Fund No. 63. The bonds will carry an interest rate of 2% and will have a maturity interest rate of 2%. The bonds will mature on October 2, 2028. The bonds will be 100% convertible into 1,692,047 common shares of the company at a conversion price of KRW 1,182. The conversion period for the bonds will be between October 2, 2026 to September 2, 2028. The transaction has been approved by the board of directors of the company and is expected to close on October 2, 2025. The securities issued in the transaction will be held for a lockup period of 1 year. On the same date, the company will also issue 4,734,848 common shares at an issue price of KRW 1,056 for gross proceeds of KRW 4,999,999,488. The transaction includes participation from new investor, Aria New Technology Fund No. 95. The transaction has been approved by the board of directors of the company and is expected to close on October 2, 2025. The securities issued in the transaction will be held for a lockup period of 1 year.New Risk • Aug 31New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩17b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩17b free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Shareholders have been substantially diluted in the past year (93% increase in shares outstanding). Minor Risks Revenue is less than US$5m (₩1.5b revenue, or US$1.1m). Market cap is less than US$100m (₩39.5b market cap, or US$28.5m).お知らせ • Jul 03SCM Lifescience Co., Ltd. (KOSDAQ:A298060) completed the acquisition of poong jun pharmaceutica wholesale co., ltd from Kumho HT, Inc. (KOSE:A214330).SCM Lifescience Co., Ltd. (KOSDAQ:A298060) agreed to acquire poong jun pharmaceutica wholesale co., ltd from Kumho HT, Inc. (KOSE:A214330) for KRW 8.2 billion on June 17, 2025. A cash consideration of KRW 8.21 billion will be paid by SCM Lifescience Co., Ltd. As part of consideration, KRW 8.21 billion is paid towards common equity of poong jun pharmaceutica wholesale co., ltd. The transaction will be financed through equity investment of KRW 8.21 billion. For the period ending December 31, 2024, poong jun pharmaceutica wholesale co., ltd reported total revenue of KRW 37.02 billion and net income of KRW 630 million. As of December 31, 2024, poong jun pharmaceutica wholesale co., ltd reported total debt of KRW 7.95 billion and total assets of KRW 17.37 billion. The expected completion of the transaction is July 1, 2025. SCM Lifescience Co., Ltd. (KOSDAQ:A298060) completed the acquisition of poong jun pharmaceutica wholesale co., ltd from Kumho HT, Inc. (KOSE:A214330) on July 1, 2025. Kumho HT, Inc. has received the balance of payment for the shares.お知らせ • Jun 27SCM Lifescience Co., Ltd. announced that it has received KRW 2.999999525 billion in fundingOn June 25, 2025. SCM Lifescience Co., Ltd. has closed the transaction.お知らせ • Jun 18SCM Lifescience Co., Ltd. (KOSDAQ:A298060) agreed to acquire poong jun pharmaceutica wholesale co., ltd from Kumho HT, Inc. (KOSE:A214330) for KRW 8.2 billion.SCM Lifescience Co., Ltd. (KOSDAQ:A298060) agreed to acquire poong jun pharmaceutica wholesale co., ltd from Kumho HT, Inc. (KOSE:A214330) for KRW 8.2 billion on June 17, 2025. A cash consideration of KRW 8.21 billion will be paid by SCM Lifescience Co., Ltd. As part of consideration, KRW 8.21 billion is paid towards common equity of poong jun pharmaceutica wholesale co., ltd. The transaction will be financed through equity investment of KRW 8.21 billion. For the period ending December 31, 2024, poong jun pharmaceutica wholesale co., ltd reported total revenue of KRW 37.02 billion and net income of KRW 630 million. As of December 31, 2024, poong jun pharmaceutica wholesale co., ltd reported total debt of KRW 7.95 billion and total assets of KRW 17.37 billion. The expected completion of the transaction is July 1, 2025.お知らせ • Jun 12SCM Lifescience Co., Ltd. announced that it expects to receive KRW 7.99999923 billion in fundingSCM Lifescience Co., Ltd announced a private placement to issue 10,738,254 common shares at an issue price of KRW 745 per share for gross proceeds of KRW 7,999,999,230 June 10, 2025. The transaction will include participation from new investor Marcia New Technology Fund No. 77 The transaction has been approved by shareholders, expected to close on June 25, 2025. 4,026,845 - The transaction will issue 4,026,845 shares at an issue price of KRW 745 per share for gross proceeds of KRW 2,999,999,525. The transaction will include participation from new investor Marcia New Technology Fund No. 77 The transaction has been approved by shareholders, expected to close on June 25, 2025. 6,711,409 - The transaction will issue 6,711,409 shares at an issue price of KRW 745 per share for gross proceeds of KRW 4,999,999,705.The transaction will include participation from new investor Marcia New Technology Fund No. 77 The transaction has been approved by shareholders, expected to close on July 25, 2025.New Risk • Apr 15New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 36% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Shareholders have been substantially diluted in the past year (36% increase in shares outstanding). Revenue is less than US$1m (₩825m revenue, or US$578k). Minor Risk Market cap is less than US$100m (₩28.5b market cap, or US$20.0m).お知らせ • Apr 15SCM Lifescience Co., Ltd. has completed a Follow-on Equity Offering in the amount of KRW 999.99999 million.SCM Lifescience Co., Ltd. has completed a Follow-on Equity Offering in the amount of KRW 999.99999 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 990,099 Price\Range: KRW 1010 Transaction Features: Subsequent Direct Listingお知らせ • Mar 26SCM Lifescience Co., Ltd. announced that it has received KRW 7.9999997 billion in fundingOn March 24, 2025, SCM Lifescience Co., Ltd., closed the transaction.New Risk • Mar 21New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Revenue is less than US$1m (₩889m revenue, or US$608k). Minor Risk Market cap is less than US$100m (₩27.3b market cap, or US$18.7m).お知らせ • Mar 18SCM Lifescience Co., Ltd., Annual General Meeting, Mar 31, 2025SCM Lifescience Co., Ltd., Annual General Meeting, Mar 31, 2025, at 10:00 Tokyo Standard Time. Location: conference room, 7-7, gaetbeol-ro 145beon-gil, yeonsu-gu, incheon South KoreaNew Risk • Dec 16New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (14% average weekly change). Minor Risk Market cap is less than US$100m (₩40.9b market cap, or US$28.5m).Reported Earnings • Nov 02Third quarter 2024 earnings released: ₩150 loss per share (vs ₩393 loss in 3Q 2023)Third quarter 2024 results: ₩150 loss per share (improved from ₩393 loss in 3Q 2023). Net loss: ₩3.07b (loss narrowed 50% from 3Q 2023). Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has fallen by 48% per year, which means it is significantly lagging earnings.分析記事 • Nov 01SCM Lifescience (KOSDAQ:298060) Has Debt But No Earnings; Should You Worry?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...分析記事 • Jul 05Is SCM Lifescience (KOSDAQ:298060) Using Too Much Debt?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Reported Earnings • May 18First quarter 2024 earnings released: ₩157 loss per share (vs ₩461 loss in 1Q 2023)First quarter 2024 results: ₩157 loss per share (improved from ₩461 loss in 1Q 2023). Net loss: ₩3.21b (loss narrowed 43% from 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has fallen by 52% per year, which means it is performing significantly worse than earnings.New Risk • Mar 27New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩12b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩12b free cash flow). Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 11% per year over the past 5 years. Revenue is less than US$1m (₩696m revenue, or US$516k). Minor Risks Shareholders have been diluted in the past year (41% increase in shares outstanding). Market cap is less than US$100m (₩61.6b market cap, or US$45.7m).分析記事 • Feb 29Is SCM Lifescience (KOSDAQ:298060) Using Debt In A Risky Way?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...New Risk • Nov 12New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 41% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩11b free cash flow). Share price has been highly volatile over the past 3 months (13% average weekly change). Revenue has declined by 24% over the past year. Revenue is less than US$1m (₩352m revenue, or US$267k). Minor Risks Shareholders have been diluted in the past year (41% increase in shares outstanding). Market cap is less than US$100m (₩59.9b market cap, or US$45.5m).New Risk • Nov 10New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩11b free cash flow). Share price has been highly volatile over the past 3 months (13% average weekly change). Revenue has declined by 24% over the past year. Revenue is less than US$1m (₩352m revenue, or US$267k). Minor Risk Market cap is less than US$100m (₩37.8b market cap, or US$28.7m).お知らせ • Sep 08SCM Lifescience Co., Ltd. has completed a Follow-on Equity Offering in the amount of KRW 18.36 billion.SCM Lifescience Co., Ltd. has completed a Follow-on Equity Offering in the amount of KRW 18.36 billion. Security Name: Common Stock Security Type: Common Stock Securities Offered: 4,800,000 Price\Range: KRW 3825 Discount Per Security: KRW 79.2 Transaction Features: Rights OfferingNew Risk • Jul 13New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩12b free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Revenue has declined by 16% over the past year. Revenue is less than US$1m (₩380m revenue, or US$298k). Minor Risk Market cap is less than US$100m (₩75.6b market cap, or US$59.3m).Is New 90 Day High Low • Feb 24New 90-day low: ₩33,550The company is down 4.0% from its price of ₩35,050 on 26 November 2020. The South Korean market is up 17% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Biotechs industry, which is down 7.0% over the same period.Is New 90 Day High Low • Jan 04New 90-day high: ₩55,400The company is up 85% from its price of ₩30,000 on 06 October 2020. The South Korean market is up 21% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 23% over the same period.Is New 90 Day High Low • Dec 03New 90-day high: ₩37,000The company is up 10.0% from its price of ₩33,750 on 04 September 2020. The South Korean market is up 11% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Biotechs industry, which is up 2.0% over the same period.株主還元A298060KR BiotechsKR 市場7D-17.3%5.2%6.7%1Y-26.7%29.1%181.2%株主還元を見る業界別リターン: A298060過去 1 年間で29.1 % の収益を上げたKR Biotechs業界を下回りました。リターン対市場: A298060は、過去 1 年間で181.2 % のリターンを上げたKR市場を下回りました。価格変動Is A298060's price volatile compared to industry and market?A298060 volatilityA298060 Average Weekly Movement10.9%Biotechs Industry Average Movement11.6%Market Average Movement9.4%10% most volatile stocks in KR Market16.6%10% least volatile stocks in KR Market4.9%安定した株価: A298060 、 KR市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: A298060の 週次ボラティリティ ( 11% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト2014n/aByeong-gwan Sonwww.scmlifescience.comSCMライフサイエンス株式会社は、幹細胞治療事業、CMO事業、受託研究・コンサルティング事業、化粧品事業を展開している。幹細胞分離技術を用いた同種幹細胞治療薬の開発、免疫疾患や組織再生を対象とした臨床試験の実施、製造管理や品質保証試験を行うCMOサービスの提供、成体幹細胞研究サービスの提供などを行っている。また、皮膚細胞科学サービスも提供している。同社は2014年に設立され、韓国の仁川に本社を置いている。もっと見るPoongjeon Pharmacy CO.,LTD. 基礎のまとめPoongjeon PharmacyLTD の収益と売上を時価総額と比較するとどうか。A298060 基礎統計学時価総額₩31.21b収益（TTM）-₩8.24b売上高(TTM)₩1.54b17.6xP/Sレシオ-3.3xPER（株価収益率A298060 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計A298060 損益計算書（TTM）収益₩1.54b売上原価₩1.02b売上総利益₩518.50mその他の費用₩8.76b収益-₩8.24b直近の収益報告Jun 30, 2025次回決算日該当なし一株当たり利益（EPS）-931.80グロス・マージン33.60%純利益率-533.88%有利子負債／自己資本比率0%A298060 の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/26 16:20終値2026/05/26 00:00収益2025/06/30年間収益2024/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Poongjeon Pharmacy CO.,LTD. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Board Change • May 19No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 1 highly experienced director. No independent directors (3 non-independent directors). CEO & Chairman Byeong-gwan Son was the last director to join the board, commencing their role in 2014. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
お知らせ • Mar 10SCM Lifescience Co., Ltd., Annual General Meeting, Mar 24, 2026SCM Lifescience Co., Ltd., Annual General Meeting, Mar 24, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 7-7, gaetbeol-ro 145beon-gil, yeonsu-gu, incheon South Korea
New Risk • Feb 15New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (116% increase in shares outstanding). Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Revenue is less than US$5m (₩1.5b revenue, or US$1.1m). Market cap is less than US$100m (₩37.3b market cap, or US$25.9m).
お知らせ • Sep 16SCM Lifescience Co., Ltd. announced that it has received KRW 4 billion in fundingOn September 15, 2025, SCM Lifescience Co., Ltd. closed the transaction.
お知らせ • Sep 08SCM Lifescience Co., Ltd. announced that it expects to receive KRW 6.999999488 billion in fundingSCM Lifescience Co., Ltd announced a private placement to issue series 2 bearer unsecured convertible bonds for gross proceeds of KRW 2,000,000,000 on September 8, 2025. The transaction will include participation from new investor, Koni New Technology Fund No. 63. The bonds will carry an interest rate of 2% and will have a maturity interest rate of 2%. The bonds will mature on October 2, 2028. The bonds will be 100% convertible into 1,692,047 common shares of the company at a conversion price of KRW 1,182. The conversion period for the bonds will be between October 2, 2026 to September 2, 2028. The transaction has been approved by the board of directors of the company and is expected to close on October 2, 2025. The securities issued in the transaction will be held for a lockup period of 1 year. On the same date, the company will also issue 4,734,848 common shares at an issue price of KRW 1,056 for gross proceeds of KRW 4,999,999,488. The transaction includes participation from new investor, Aria New Technology Fund No. 95. The transaction has been approved by the board of directors of the company and is expected to close on October 2, 2025. The securities issued in the transaction will be held for a lockup period of 1 year.
New Risk • Aug 31New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩17b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩17b free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Shareholders have been substantially diluted in the past year (93% increase in shares outstanding). Minor Risks Revenue is less than US$5m (₩1.5b revenue, or US$1.1m). Market cap is less than US$100m (₩39.5b market cap, or US$28.5m).
Board Change • May 19No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 1 highly experienced director. No independent directors (3 non-independent directors). CEO & Chairman Byeong-gwan Son was the last director to join the board, commencing their role in 2014. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
お知らせ • Mar 10SCM Lifescience Co., Ltd., Annual General Meeting, Mar 24, 2026SCM Lifescience Co., Ltd., Annual General Meeting, Mar 24, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 7-7, gaetbeol-ro 145beon-gil, yeonsu-gu, incheon South Korea
New Risk • Feb 15New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (116% increase in shares outstanding). Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Revenue is less than US$5m (₩1.5b revenue, or US$1.1m). Market cap is less than US$100m (₩37.3b market cap, or US$25.9m).
お知らせ • Sep 16SCM Lifescience Co., Ltd. announced that it has received KRW 4 billion in fundingOn September 15, 2025, SCM Lifescience Co., Ltd. closed the transaction.
お知らせ • Sep 08SCM Lifescience Co., Ltd. announced that it expects to receive KRW 6.999999488 billion in fundingSCM Lifescience Co., Ltd announced a private placement to issue series 2 bearer unsecured convertible bonds for gross proceeds of KRW 2,000,000,000 on September 8, 2025. The transaction will include participation from new investor, Koni New Technology Fund No. 63. The bonds will carry an interest rate of 2% and will have a maturity interest rate of 2%. The bonds will mature on October 2, 2028. The bonds will be 100% convertible into 1,692,047 common shares of the company at a conversion price of KRW 1,182. The conversion period for the bonds will be between October 2, 2026 to September 2, 2028. The transaction has been approved by the board of directors of the company and is expected to close on October 2, 2025. The securities issued in the transaction will be held for a lockup period of 1 year. On the same date, the company will also issue 4,734,848 common shares at an issue price of KRW 1,056 for gross proceeds of KRW 4,999,999,488. The transaction includes participation from new investor, Aria New Technology Fund No. 95. The transaction has been approved by the board of directors of the company and is expected to close on October 2, 2025. The securities issued in the transaction will be held for a lockup period of 1 year.
New Risk • Aug 31New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩17b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩17b free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Shareholders have been substantially diluted in the past year (93% increase in shares outstanding). Minor Risks Revenue is less than US$5m (₩1.5b revenue, or US$1.1m). Market cap is less than US$100m (₩39.5b market cap, or US$28.5m).
お知らせ • Jul 03SCM Lifescience Co., Ltd. (KOSDAQ:A298060) completed the acquisition of poong jun pharmaceutica wholesale co., ltd from Kumho HT, Inc. (KOSE:A214330).SCM Lifescience Co., Ltd. (KOSDAQ:A298060) agreed to acquire poong jun pharmaceutica wholesale co., ltd from Kumho HT, Inc. (KOSE:A214330) for KRW 8.2 billion on June 17, 2025. A cash consideration of KRW 8.21 billion will be paid by SCM Lifescience Co., Ltd. As part of consideration, KRW 8.21 billion is paid towards common equity of poong jun pharmaceutica wholesale co., ltd. The transaction will be financed through equity investment of KRW 8.21 billion. For the period ending December 31, 2024, poong jun pharmaceutica wholesale co., ltd reported total revenue of KRW 37.02 billion and net income of KRW 630 million. As of December 31, 2024, poong jun pharmaceutica wholesale co., ltd reported total debt of KRW 7.95 billion and total assets of KRW 17.37 billion. The expected completion of the transaction is July 1, 2025. SCM Lifescience Co., Ltd. (KOSDAQ:A298060) completed the acquisition of poong jun pharmaceutica wholesale co., ltd from Kumho HT, Inc. (KOSE:A214330) on July 1, 2025. Kumho HT, Inc. has received the balance of payment for the shares.
お知らせ • Jun 27SCM Lifescience Co., Ltd. announced that it has received KRW 2.999999525 billion in fundingOn June 25, 2025. SCM Lifescience Co., Ltd. has closed the transaction.
お知らせ • Jun 18SCM Lifescience Co., Ltd. (KOSDAQ:A298060) agreed to acquire poong jun pharmaceutica wholesale co., ltd from Kumho HT, Inc. (KOSE:A214330) for KRW 8.2 billion.SCM Lifescience Co., Ltd. (KOSDAQ:A298060) agreed to acquire poong jun pharmaceutica wholesale co., ltd from Kumho HT, Inc. (KOSE:A214330) for KRW 8.2 billion on June 17, 2025. A cash consideration of KRW 8.21 billion will be paid by SCM Lifescience Co., Ltd. As part of consideration, KRW 8.21 billion is paid towards common equity of poong jun pharmaceutica wholesale co., ltd. The transaction will be financed through equity investment of KRW 8.21 billion. For the period ending December 31, 2024, poong jun pharmaceutica wholesale co., ltd reported total revenue of KRW 37.02 billion and net income of KRW 630 million. As of December 31, 2024, poong jun pharmaceutica wholesale co., ltd reported total debt of KRW 7.95 billion and total assets of KRW 17.37 billion. The expected completion of the transaction is July 1, 2025.
お知らせ • Jun 12SCM Lifescience Co., Ltd. announced that it expects to receive KRW 7.99999923 billion in fundingSCM Lifescience Co., Ltd announced a private placement to issue 10,738,254 common shares at an issue price of KRW 745 per share for gross proceeds of KRW 7,999,999,230 June 10, 2025. The transaction will include participation from new investor Marcia New Technology Fund No. 77 The transaction has been approved by shareholders, expected to close on June 25, 2025. 4,026,845 - The transaction will issue 4,026,845 shares at an issue price of KRW 745 per share for gross proceeds of KRW 2,999,999,525. The transaction will include participation from new investor Marcia New Technology Fund No. 77 The transaction has been approved by shareholders, expected to close on June 25, 2025. 6,711,409 - The transaction will issue 6,711,409 shares at an issue price of KRW 745 per share for gross proceeds of KRW 4,999,999,705.The transaction will include participation from new investor Marcia New Technology Fund No. 77 The transaction has been approved by shareholders, expected to close on July 25, 2025.
New Risk • Apr 15New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 36% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Shareholders have been substantially diluted in the past year (36% increase in shares outstanding). Revenue is less than US$1m (₩825m revenue, or US$578k). Minor Risk Market cap is less than US$100m (₩28.5b market cap, or US$20.0m).
お知らせ • Apr 15SCM Lifescience Co., Ltd. has completed a Follow-on Equity Offering in the amount of KRW 999.99999 million.SCM Lifescience Co., Ltd. has completed a Follow-on Equity Offering in the amount of KRW 999.99999 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 990,099 Price\Range: KRW 1010 Transaction Features: Subsequent Direct Listing
お知らせ • Mar 26SCM Lifescience Co., Ltd. announced that it has received KRW 7.9999997 billion in fundingOn March 24, 2025, SCM Lifescience Co., Ltd., closed the transaction.
New Risk • Mar 21New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Revenue is less than US$1m (₩889m revenue, or US$608k). Minor Risk Market cap is less than US$100m (₩27.3b market cap, or US$18.7m).
お知らせ • Mar 18SCM Lifescience Co., Ltd., Annual General Meeting, Mar 31, 2025SCM Lifescience Co., Ltd., Annual General Meeting, Mar 31, 2025, at 10:00 Tokyo Standard Time. Location: conference room, 7-7, gaetbeol-ro 145beon-gil, yeonsu-gu, incheon South Korea
New Risk • Dec 16New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (14% average weekly change). Minor Risk Market cap is less than US$100m (₩40.9b market cap, or US$28.5m).
Reported Earnings • Nov 02Third quarter 2024 earnings released: ₩150 loss per share (vs ₩393 loss in 3Q 2023)Third quarter 2024 results: ₩150 loss per share (improved from ₩393 loss in 3Q 2023). Net loss: ₩3.07b (loss narrowed 50% from 3Q 2023). Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has fallen by 48% per year, which means it is significantly lagging earnings.
分析記事 • Nov 01SCM Lifescience (KOSDAQ:298060) Has Debt But No Earnings; Should You Worry?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...
分析記事 • Jul 05Is SCM Lifescience (KOSDAQ:298060) Using Too Much Debt?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Reported Earnings • May 18First quarter 2024 earnings released: ₩157 loss per share (vs ₩461 loss in 1Q 2023)First quarter 2024 results: ₩157 loss per share (improved from ₩461 loss in 1Q 2023). Net loss: ₩3.21b (loss narrowed 43% from 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has fallen by 52% per year, which means it is performing significantly worse than earnings.
New Risk • Mar 27New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩12b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩12b free cash flow). Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 11% per year over the past 5 years. Revenue is less than US$1m (₩696m revenue, or US$516k). Minor Risks Shareholders have been diluted in the past year (41% increase in shares outstanding). Market cap is less than US$100m (₩61.6b market cap, or US$45.7m).
分析記事 • Feb 29Is SCM Lifescience (KOSDAQ:298060) Using Debt In A Risky Way?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
New Risk • Nov 12New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 41% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩11b free cash flow). Share price has been highly volatile over the past 3 months (13% average weekly change). Revenue has declined by 24% over the past year. Revenue is less than US$1m (₩352m revenue, or US$267k). Minor Risks Shareholders have been diluted in the past year (41% increase in shares outstanding). Market cap is less than US$100m (₩59.9b market cap, or US$45.5m).
New Risk • Nov 10New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩11b free cash flow). Share price has been highly volatile over the past 3 months (13% average weekly change). Revenue has declined by 24% over the past year. Revenue is less than US$1m (₩352m revenue, or US$267k). Minor Risk Market cap is less than US$100m (₩37.8b market cap, or US$28.7m).
お知らせ • Sep 08SCM Lifescience Co., Ltd. has completed a Follow-on Equity Offering in the amount of KRW 18.36 billion.SCM Lifescience Co., Ltd. has completed a Follow-on Equity Offering in the amount of KRW 18.36 billion. Security Name: Common Stock Security Type: Common Stock Securities Offered: 4,800,000 Price\Range: KRW 3825 Discount Per Security: KRW 79.2 Transaction Features: Rights Offering
New Risk • Jul 13New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩12b free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Revenue has declined by 16% over the past year. Revenue is less than US$1m (₩380m revenue, or US$298k). Minor Risk Market cap is less than US$100m (₩75.6b market cap, or US$59.3m).
Is New 90 Day High Low • Feb 24New 90-day low: ₩33,550The company is down 4.0% from its price of ₩35,050 on 26 November 2020. The South Korean market is up 17% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Biotechs industry, which is down 7.0% over the same period.
Is New 90 Day High Low • Jan 04New 90-day high: ₩55,400The company is up 85% from its price of ₩30,000 on 06 October 2020. The South Korean market is up 21% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 23% over the same period.
Is New 90 Day High Low • Dec 03New 90-day high: ₩37,000The company is up 10.0% from its price of ₩33,750 on 04 September 2020. The South Korean market is up 11% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Biotechs industry, which is up 2.0% over the same period.
